Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS

(REGN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Regeneron Pharmaceuticals : to Report Third Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on November 5, 2019

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/10/2019 | 09:31am EDT

TARRYTOWN, N.Y., Oct. 10, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2019 financial and operating results on Tuesday, November 5, 2019, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.

Conference Call Information
To access this call, dial (800) 708-4540 (U.S.) or (847) 619-6397 (International). A link to the webcast may be accessed from the 'Investors and Media' page of Regeneron's website at http://investor.regeneron.com/events.cfm. A replay of the conference call and webcast will be archived on the Company's website.

About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Contact Information:




Investor Relations

Corporate Communications

Justin Holko

Hala Mirza

914.847.7786

914.847.3422

justin.holko@regeneron.com

hala.mirza@regeneron.com

 

Cision
View original content:http://www.prnewswire.com/news-releases/regeneron-to-report-third-quarter-2019-financial-and-operating-results-and-host-conference-call-and-webcast-on-november-5-2019-300934401.html

SOURCE Regeneron Pharmaceuticals, Inc.


© PRNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
10/18REGENERON PHARMACEUTICALS : Announces Upcoming Investor Conference Presentations
PR
10/10REGENERON PHARMACEUTICALS : to Report Third Quarter 2019 Financial and Operating..
PR
09/23REGENERON PHARMACEUTICALS : CHMP Recommends Approval of Dupixent for Severe Chro..
AQ
09/23REGENERON PHARMACEUTICALS : Lancet Publishes Results from Two Positive Phase 3 T..
AQ
09/23SANOFI : - CHMP recommends approval of Dupixent for severe chronic rhinosinusiti..
AQ
09/20REGENERON PHARMACEUTICALS : The Lancet Publishes Results from Two Positive Phase..
PU
09/20REGENERON PHARMACEUTICALS : Sanofi Get Positive CHMP Opinion for Dupixent
DJ
09/20REGENERON PHARMACEUTICALS : CHMP Recommends Approval of Dupixent® (dupilumab) fo..
PR
09/19Animal health sector aims to emulate Zoetis biotech leap
RE
09/18REGENERON PHARMACEUTICALS : Educational Campaign Helps Teens and Their Caregiver..
PR
More news